论文部分内容阅读
目的探讨吉西他滨联合清蛋白结合型紫杉醇的临床疗效及安全性。方法选取江苏大学附属医院2005—2015年收治的胰腺癌患者100例,根据随机数字表分为对照组和研究组,各50例。对照组患者给予吉西他滨联合多西紫杉醇治疗,研究组患者给予吉西他滨联合清蛋白结合型紫杉醇治疗,两组患者均持续化疗4个周期。比较两组患者临床疗效、急性与亚急性毒性反应及其分级。结果研究组患者临床疗效优于对照组(P<0.05)。研究组患者中性粒细胞分数减少、血小板计数减少、贫血、脱发、周围神经病变及肝功能异常分级程度轻于对照组(P<0.05)。结论采用吉西他滨联合清蛋白结合型紫杉醇治疗胰腺癌的临床疗效确切,可有效降低毒副作用及其严重程度,安全性好。
Objective To investigate the clinical efficacy and safety of gemcitabine combined with albumin-bound paclitaxel. Methods 100 cases of pancreatic cancer patients who were admitted to Affiliated Hospital of Jiangsu University from 2005 to 2015 were divided into control group and study group according to random number table. Patients in the control group were treated with gemcitabine combined with docetaxel. Patients in the study group were treated with gemcitabine combined with albumin-bound paclitaxel. Both groups were treated with 4 cycles of chemotherapy. The clinical efficacy, acute and subacute toxicities and their grades were compared between the two groups. Results The clinical efficacy of the study group was better than that of the control group (P <0.05). In the study group, the neutrophil fraction decreased, the platelet count decreased, the degree of anemia, alopecia, peripheral neuropathy and liver dysfunction grading was lower than that of the control group (P <0.05). Conclusion The clinical efficacy of gemcitabine combined with albumin-bound paclitaxel in the treatment of pancreatic cancer is definite, which can effectively reduce the side effects and the severity of the disease and is safe.